Drug intelligence / Profile preview

SUL-259

Development stage: Preclinical
Lead developer: Sulfateq
Modality: Small Molecules

Overview

SUL-259 is a small molecule drug candidate being developed by Sulfateq for the treatment of chronic obstructive pulmonary disease (COPD). The compound is part of a proprietary library of molecules designed to address mitochondrial dysfunction, utilizing a unique mechanism of action derived from natural hibernation and mitochondrial stress-coping mechanisms. By preserving mitochondrial integrity and cellular energy production under pathological stress, SUL-259 aims to mitigate the cellular damage and inflammation associated with COPD. As of early 2024, the program is in the discovery stage of development.

Beyond the preview

Go deeper on SUL-259.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUL-259.

Explore the full profile